Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparison of Yasmin vs Cyproterone compound on metabolic syndrome in women with polycystic ovary syndrome
IRCT201204171760N17Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of drospirenone and cyproterone in cardiometabolic risk (CMR) and polycystic ovary syndrome (PCOS) (2 arms), sponsored by Babol University of Medical Sciences. Primary endpoint: Metabolic syndrome parameters. Started Apr 2012; status: completed.
02
Drugs
drospirenonecyproterone
03
Conditions
cardiometabolic risk (CMR)polycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on IRCT201204171760N17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201204171760N17.